Prelude Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Prelude Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,641	Closed	-$6.33M	–	1254
2025 Q4	$6.33M	Buy	+28,641	New	+$4.63M	0.47%	34
2017 Q2	–	Sell	-81	Closed	-$13K	–	1618
2017 Q1	$13K	Buy	+81	New	+$14.2K	﹤0.01%	1329
2016 Q1	–	Sell	-9	Closed	-$3K	–	1282
2015 Q4	$3K	Buy	+9	New	+$2.7K	﹤0.01%	1361

Prelude Capital Management's CDTX Position: Q1 2026 in Review

Prelude Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 28,641 shares — an estimated $6.33M sold.

Prelude Capital Management first reported a position in CDTX in Q4 2015 and held it in 3 quarters. The position peaked at $6.33M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Prelude Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 28,641 Cidara Therapeutics shares in Q1 2026, an estimated $6.33M.
Prelude Capital Management first reported a position in Cidara Therapeutics in Q4 2015 and held it in 3 quarters.
Prelude Capital Management's Cidara Therapeutics position peaked at $6.33M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.